HCS Pharma is proud to be a part of the CHOPIN Project (CHolesterol Personalized INnovation). Selected as one of the ten most innovative health research programs by the ANR (French Research Agency), the project will receive more than €8 million euros through the second wave of the “Investissements d’Avenir” (i.e. “Investing for the future” ) program of the French government.

logo_IDT

Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.

HCS Pharma is involved in the development and automation of new innovative cellular 3D models of familial hypercholesterolemia in order to perform phenotypic screening. Méryl Roudaut, Ms, will be a key person in this project for HCS Pharma since he will start his Ph.D. training in tight collaboration with HCS Pharma and l’institut du thorax under the supervision of Pr Bertrand Cariou, M.D-Ph.D., and Dr Karim Si-Tayeb, PhD.

HCS Pharma team is really proud to integrate such a nice project and to work with the excellence of French researchers, as Pr Bertrand Cariou and his team.

Out of the 51 projects that applied, only 10 were selected by an international jury. Scientific skills were of course important but the economic potential as well as public/private links were also at stake.

*l’institut du thorax is part of both French Health and Scientific Research Institutes  ̶  Inserm and CNRS  ̶  Nantes University and Nantes University Hospital


Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

7 Comments

Presentation of the French Plan for Genomic Medicine 2025 | HCS-pharma · August 18, 2016 at 9:00 am

[…] to put France in the learder group of countries involved in genomic medicine. As we integrate CHOPIN Project (CHolesterol Personalized INnovation), We are proud to be a part of this French Plan for Genomic Medicine […]

PhD started for Meryl | HCS-pharma · September 5, 2016 at 9:22 am

[…] patient with familial hypercholesterolemia. This project is a little part of big project called CHOPIN! Thank you to them to give the opportunity to Meryl to do his Ph D and to start a collaboration […]

Goodbye 2016, welcome 2017 ! | HCS-pharma · January 16, 2017 at 2:58 pm

[…] 2016 is ending with very good results for HCS Pharma, with a nice and motivated team, the effective launch of partnerships with the “Insitut du Thorax” in Nantes and Inserm U991 in Rennes, and customers partners that reiterate their trust. 2017 will be the year […]

Feedback of Advances in Cell screening congress organized by ELRIG | HCS-pharma · May 30, 2017 at 12:09 pm

[…] As an example Professor Neil Carragher from Edinburgh University has explained their phenotypic screen on glioma using patient derived culture, cell painting as described by Anne Carpenter from the Broad Institute of MIT as read-outs and machine learning for image and data analysis. Another topic of interest was from Vilja Pietiäinen (Institute for Molecular Medicine Finland – FIMM) showing their proof of concept for personalized medicine in oncology, on leukemia and solid tumors. They used genomic and phenotypic screening on patients derived cells on 2D and 3D culture with machine learning to choose the drugs which are the most effective for the patient. We were also very interested by topics about advances in 3D culture, especially for human hepatocytes as presented by Volker Laushke. Indeed, 3D culture of PHH and human derived PHH are part of two subjects from our R&D project InnovCell 3D, and Chopin. […]

Our first scientific advisory board meeting in HCS Pharma | HCS-pharma · September 12, 2017 at 9:00 am

[…] are working with Karim to differentiate hepatocytes from patients cells (iPS) in a 3D context in a really great collaborative RHU project (CHOPIN). We are collaborating with Romeo, David and Georg to develop new human neurodegenerative cellular […]

Feedback of SIBS 2017 in Zurich last week | HCS-pharma · October 26, 2017 at 10:18 am

[…] I presented our collaborative work with Dr Karim Si-Tayeb, researcher from Institut du Thorax (CHOPIN project) on differentiation of iPS in hepatocytes in 3D culture for metabolic diseases screening. Karim has […]

Meet me in High Content Analysis and 3D screening Conference in Boston next week! | HCS-pharma · December 13, 2017 at 11:59 am

[…] poster on our collaborative work with Dr Karim Si-Tayeb, researcher from Institut du Thorax (CHOPIN project) on differentiation of iPS in hepatocytes in 3D culture for metabolic diseases […]

Leave a Reply